MedTrace Logo

Intranasal Insulin in Parkinson's Disease

NCT04251585 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-02-11

Study results available
· View outcomes & findings →

Summary

This project will investigate exploratory outcomes related to the effect of intranasal insulin on cognition, mood, apathy and motor performance of subjects with Parkinson's disease over a 3 week period.

Conditions

  • Parkinson Disease

Interventions

DRUG

Regular Novolin R

Intranasal insulin

DRUG

Placebo

Intranasal placebo (0.9% saline)

Sponsors & Collaborators

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Julia C Johnson, MD · HealthPartners Neurology

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-04
Primary Completion
2024-08-27
Completion
2024-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04251585 on ClinicalTrials.gov